We hypothesize that epileptiform abnormalities (EAs) in the electroencephalogram (EEG) during the acute period following traumatic brain injury (TBI) independently predict first-year post-traumatic epilepsy (PTE 1 ). We analyze PTE 1 risk factors in two cohorts matched for TBI severity and age (n 5 50). EAs independently predict risk for PTE 1 (odds ratio [OR], 3.16 [0.99, 11 .68]); subdural hematoma is another independent risk factor (OR, 4.13 [1.18, 39.33]). Differences in EA rates are apparent within 5 days following TBI. Our results suggest that increased EA prevalence identifies patients at increased risk for PTE 1 , and that EAs acutely post-TBI can identify patients most likely to benefit from antiepileptogenesis drug trials. ANN NEUROL 2018;83:858-862 S evere brain trauma is a leading cause of death and disability in adults and children worldwide.
, and that EAs acutely post-TBI can identify patients most likely to benefit from antiepileptogenesis drug trials. ANN NEUROL 2018; 83:858-862 S evere brain trauma is a leading cause of death and disability in adults and children worldwide. 1 Post-traumatic epilepsy (PTE) is one of the most disabling complications in survivors and can be difficult to treat. 2 PTE rates are reported in up to 20% of patients, with increased risk based on brain injury severity, surgical intervention, time since traumatic brain injury (TBI), and younger age. [3] [4] [5] [6] Although some risk factors are known, we need to better stratify patients at highest risk for PTE to better understand antiepileptogenesis and develop therapeutic agents. Although there is great interest in interventions to prevent post-TBI epileptogenesis, clinical trials have been plagued by financial and logistical barriers, with estimates upward of $20 million. 4, 7 Efforts to prevent epileptogenesis would be greatly aided by identification of acute biomarkers that identify patients at high risk for developing PTE, thus enriching the population eligible for clinical trials in a cost-effective manner. 8 Epileptiform abnormalities (EAs), which include sporadic epileptiform discharges (spikes and sharp waves), periodic epileptiform discharges, and rhythmic patterns, are common following all types of acute brain injury, including TBI. 9 Recent work from our group suggests that 
Methods
We evaluated EEG reports and medical records from 50 patients with TBI at a tertiary care center (Massachusetts General Hospital Neurosciences and Surgical ICUs) who met study inclusion criteria between 2011 and 2015. Inclusion criteria were: age 18 years, TBI on presentation, and EEG monitoring during the initial hospital admission for TBI. Retrospective collection and analysis of clinical data were performed under a protocol approved by the local institutional review board. Among patients meeting the inclusion criteria, we first evaluated consecutive (based on hospital admission) cases to identify 25 who developed PTE 1 (defined below), and subsequently evaluated consecutive cases to identify 25 controls without PTE 1 , matched by age and admission Glasgow Coma Scores (GCSs).
EEG Recordings and Report Review
EEG data were recorded using conventional 10-20 scalp electrode placement. EAs were classified according to standardized nomenclature 12 as: seizures, sporadic epileptiform discharges (EDs), lateralized or generalized periodic discharges (LPDs and GPDs), and lateralized rhythmic delta activity (LRDA). 13 We also analyzed generalized rhythmic delta activity (GRDA) and polymorphic generalized and focal slowing, but consider these separate from EAs. The presence (dark bars) or absence (light bars) of these abnormalities, as documented in daily clinical EEG reports, was tallied for each patient with "day of traumatic brain injury" marked as day 0 (Fig A) . A histogram representing the EEG distribution is shown in Figure B .
PTE 1 Definition
Patients with at least one seizure 2 to 12 months post-TBI, based on medical record review. Control subjects were patients meeting the inclusion criteria who had TBI without any documented seizures in the same period, matched for age and admission GCS (Table 1) . Patients were excluded if there were insufficient follow-up visits in the electronic health record to determine PTE 1 status. For practicality, we analyzed up to 12 months, the highest-risk period, 14 while acknowledging that this does not fully capture eventual PTE development.
Statistical Analysis
For data analysis, we used Matlab, including the Matlab Statistics Toolbox (The MathWorks, Inc., Natick, MA). We utilized uni-and multivariate logistic regression to calculate odds ratios (ORs) of the reported demographic or EEG features (candidate predictor variables for PTE 1 ). In addition to evaluating EA as a group, we analyzed individual EA subtypes (seizures, EDs, LPDs, GPDs, and LRDA). Bootstrapping was used to determine 95% confidence intervals (CIs) and p values, with a significance threshold of p 0.05.
Results

Demographic Predictors
We calculated associations between demographic variables and PTE 1 , including age, sex, admission GCS, presence of intraparenchymal hemorrhage (IPH), subdural hemorrhage (SDH), subarachnoid hemorrhage (SAH), or epidural hemorrhage (EDH; Table 1 ). The only demographic variable significantly associated with PTE 1 development is SDH (p 5 0.02; Table 1 ).
EEG Distribution
EEG acquisition days are shown for each individual and summarized for each cohort (Fig A,B) . The PTE 1 group has more days of EEG monitoring overall, possibly attributable to the continuation of EEG monitoring when epileptiform abnormalities were found.
EEG Predictors
EAs are more common in patients with PTE 1 compared to patients without PTE 1 (64% versus 36%; p 5 0.04; Fig C) . The prevalence of each EA subtype is shown in Figure D Table 2 ). By comparing multivariate logistic regression models of SDH 1 EA with the univariate regressions of EA and SDH independently, we find that SDH and EA independently contribute to increased PTE 1 risk (p 5 0.05 and p 5 0.03, respectively) without any direct relationship to each other (p 5 0.17), suggesting that model (1) is the most likely relationship between the variables: SDH and ED are independent causal factors for PTE 1 (Fig F) .
Discussion
Our results provide novel evidence that EAs may be a useful marker in identifying patients at high risk for PTE 1 .
SDH and PTE 1 SDH is significantly associated with PTE 1 in our study, in concordance with multiple other studies. 15, 16 Past studies also find associations with other variables, such as post-TBI amnesia, alcohol, and midline shift, which we did not assess. 16 Intraparenchymal hemorrhage and skull fractures are also associated with PTE 1 in other studies, 15 and although neither OR ratio in our cohort is significant (p 5 0.06 and 0.12 respectively), we are underpowered to detect such associations.
EA and PTE 1
Although the presence and prevalence of EA after TBI has been described, 17 the association with PTE 1 has not been reported. Our results demonstrate that the presence of EA following TBI signals increases risk for the development of PTE 1 . More specifically, EDs are associated with PTE 1 development. Other subtypes of EA in our data, including early seizures and LPDs, show weak associations with PTE 1 , but do not reach statistical significance, potentially because of small sample size. Interestingly, focal polymorphic slowing is also significantly associated with PTE 1 . Although often considered a nonspecific EEG pattern, focal slowing has been observed in PTE previously, 18 and a recent study showed focal slowing in areas corresponding to blood-brain barrier (BBB) disruption after TBI, which correlated with PTE 1 .
19
Our results also show that EA occur early (<5 days) after TBI, suggesting that early EEG could be a useful diagnostic tool to assess TBI patients for PTE 1 risk. TBI is a defined time-point event in which patients are known to be at risk for epileptogenesis, thus making this group prime for antiepileptogenesis trials. However, the large patient numbers needed to test interventions and unnecessary exposure to potential adverse effects in low-risk patients has been prohibitive. For example, for an antiepileptogenesis drug trial that enrolled severe TBI patients with an estimated incidence of PTE 1 at 7.1%, 20 the sample size required to detect a 50% treatment effect is 1,364 patients (Fisher's two-sided exact test, power 0.8, alpha 0.05). By contrast, if we enroll severe TBI patients with early EAs on EEG, according to our data the incidence of PTE 1 rises to 12%, and the required sample size is only 778, a decrease of 43%. 20 Although our sample size is small, retrospective in design, and needs further confirmation, our results suggest that by using EA as a biomarker to identify the subset of TBI patients at highest risk for PTE 1 development, antiepileptogenesis interventions could be feasible in a cost-effective manner.
